LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

98.39 -0.67

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

96.99

Massimo

98.97

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	14.17 51.415
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 367M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+10.43% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	993M 20B
Apertura precedente	99.06
Chiusura precedente	98.39

Notizie sul Sentiment di mercato

By Acuity

35%

65%

111 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

59.52 / 62.66 Supporto e resistenza

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2026, 22:54 UTC

Utili

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 mag 2026, 23:17 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mag 2026, 23:16 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mag 2026, 23:15 UTC

Utili

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mag 2026, 23:14 UTC

Utili

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mag 2026, 23:02 UTC

Discorsi di Mercato

Utili

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mag 2026, 22:59 UTC

Discorsi di Mercato

Utili

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mag 2026, 22:24 UTC

Utili

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Revenue Growth 47%>XRO.AU

13 mag 2026, 22:22 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mag 2026, 22:18 UTC

Utili

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mag 2026, 22:16 UTC

Utili

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mag 2026, 22:13 UTC

Utili

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mag 2026, 22:12 UTC

Utili

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mag 2026, 22:09 UTC

Utili

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mag 2026, 22:00 UTC

Utili

Cisco to Shed Jobs for All-In AI Push -- Update

13 mag 2026, 21:11 UTC

Utili

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

10.43% in crescita

Previsioni per 12 mesi

Media 109.13 USD 10.43%

Alto 135 USD

Basso 75 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

17 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 17 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

111 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation